Skip to main content

Inclisiran Dosage

Medically reviewed by Last updated on Mar 31, 2022.

Applies to the following strengths: 284 mg/1.5 mL

Usual Adult Dose for Hyperlipidemia

Initial dose: 284 mg subcutaneously once, and repeat in 3 months
Maintenance dose (after initial dose): 284 mg subcutaneously every 6 months


  • Limitations of Use: The effect of this drug on cardiovascular morbidity and mortality has not been established.
  • Low-density lipoprotein (LDL) cholesterol should be assessed when clinically indicated; the LDL-lowering effect of this drug may be measured as soon as 30 days after start and anytime thereafter without regard to the timing of the dose.

Use: As an adjunct to diet and maximally tolerated statin therapy for the treatment of patients with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL cholesterol

Renal Dose Adjustments

Mild, moderate, or severe renal dysfunction: No adjustment recommended.
ESRD: Data not available

Liver Dose Adjustments

Mild to moderate liver dysfunction: No adjustment recommended.
Severe liver dysfunction: Data not available



Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

  • This drug should be administered by a health care professional.
  • Inject subcutaneously into the abdomen, upper arm, or thigh; do not inject in areas of active skin disease/injury (e.g., sunburns, skin rashes, inflammation, skin infections).
  • If a planned dose is missed by less than 3 months, administer this dose and continue dosing according to patient's original schedule; if a planned dose is missed by more than 3 months, restart with a new dosing schedule (administer dose initially, again at 3 months, and then every 6 months).

Storage requirements:
  • Store at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F).

  • Investigations: LDL cholesterol (when clinically indicated)

Patient advice:
  • Patients of childbearing potential: Notify health care provider of known/suspected pregnancy to discuss if this drug should be stopped.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.